Summarized by Masters of Longevity from PR Newswire.
Phase 1 results showed deep PSA reductions in heavily pretreated mCRPC patients.
Key Takeaways
- 73 percent of patients had at least 50 percent PSA reductions.
- 47 percent had at least 90 percent PSA reductions and four were undetectable.
- Findings are from a small Phase 1 cohort and are not definitive.
